標(biāo)題: Titlebook: Cell and Gene Therapies; Miguel-Angel Perales,Syed A. Abutalib,Catherine Bo Book 2019 Springer Nature Switzerland AG 2019 Chimeric antigen [打印本頁] 作者: 鳥場 時間: 2025-3-21 16:07
書目名稱Cell and Gene Therapies影響因子(影響力)
書目名稱Cell and Gene Therapies影響因子(影響力)學(xué)科排名
書目名稱Cell and Gene Therapies網(wǎng)絡(luò)公開度
書目名稱Cell and Gene Therapies網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Cell and Gene Therapies被引頻次
書目名稱Cell and Gene Therapies被引頻次學(xué)科排名
書目名稱Cell and Gene Therapies年度引用
書目名稱Cell and Gene Therapies年度引用學(xué)科排名
書目名稱Cell and Gene Therapies讀者反饋
書目名稱Cell and Gene Therapies讀者反饋學(xué)科排名
作者: 灌溉 時間: 2025-3-21 21:15 作者: 障礙 時間: 2025-3-22 03:02
Chimeric Antigen Receptor T Cells: Antigen Selection, CAR Development, and Data in Neoplastic Hematogen receptor T cells provide exciting potential for curative treatments to patients with cancers found intractable with current therapies. Toxicities are one of the main limiting factors for wide applicability of CAR-T-cell therapy. The major limiting adverse events include neurotoxicity and cytokin作者: aneurysm 時間: 2025-3-22 08:11
Chimeric Antigen Receptor T Cells for Leukemias in Children: Methods, Data, and Challengesacute lymphoblastic leukemia (ALL) and 50–60% with acute myeloid leukemia (AML) experience long-term disease control after multimodal treatments that often include intensified chemotherapy. Relapsed leukemia patients pose a challenging subset of the pediatric leukemic population due to highly resist作者: Interim 時間: 2025-3-22 11:41 作者: 制定法律 時間: 2025-3-22 14:47
Chimeric Antigen Receptor T Cells for Lymphomas: Methods, Data, and Challengesll lymphocytic lymphoma (CLL/SLL) and B-cell acute lymphoblastic leukemia (B-ALL). However, targeting CD19 can result in prolonged B-cell aplasia. Given the clinical experience with the anti-CD20 monoclonal antibody rituximab with temporary B-cell aplasia, severe clinical consequence has not been ob作者: 制定法律 時間: 2025-3-22 18:40
T Cell Receptors-Gene-Modified T Cells for Cancer: Methods, Data, and Challengeslogy and new developments in synthetic biology have led to an ability to engineer T cells to express antibody-like recognition molecules linked to T cell-activating domains (chimeric antigen receptors, CARs) and tumor-specific T cell receptors (TCRs) which redirect patient-derived T cells toward the作者: 有說服力 時間: 2025-3-23 00:32 作者: 吹牛大王 時間: 2025-3-23 05:07 作者: cogent 時間: 2025-3-23 05:58
Natural Killer Cells: What Have We Learned?of the potential of immunotherapy as a therapeutic strategy. In recent years, such skepticism has diminished significantly as clinical evidence increasingly demonstrates the effectiveness of manipulating the immune system to treat a variety of established tumors. Among components of the immune syste作者: Acquired 時間: 2025-3-23 11:26 作者: Osteoporosis 時間: 2025-3-23 16:47 作者: 蕁麻 時間: 2025-3-23 20:25
Gene Therapy for Neoplastic Hematology in Transplant Setting the only therapy that has proven to be curative for hematological malignancies. The search for a more specific and, hopefully, less toxic therapeutic approach using immune system cells that are redirected toward the target of interest is needed and ongoing. This could be potentially accomplished by作者: Mutter 時間: 2025-3-24 01:05 作者: 領(lǐng)袖氣質(zhì) 時間: 2025-3-24 04:33
Miguel-Angel Perales,Syed A. Abutalib,Catherine BoAddresses key clinically relevant issues across the full spectrum of cell and gene therapies.Draws attention to the availability and implications of high-impact clinical trials.Assists trainee and pra作者: Licentious 時間: 2025-3-24 08:59 作者: addict 時間: 2025-3-24 13:39
https://doi.org/10.1007/978-3-319-54368-0Chimeric antigen receptor-T cells; Cytotoxic T cells for infections; Tumor infiltrating lymphocytes; De作者: 說笑 時間: 2025-3-24 16:51
Springer Nature Switzerland AG 2019作者: PLUMP 時間: 2025-3-24 19:20
https://doi.org/10.1057/978-1-137-57085-7anked blood. Since then technological advances have made it possible to break down the therapeutic elements of fresh blood into their constituent platelets, red cells, plasma, and clotting factors, and through apheresis, blood bankers can even provide granulocytes, lymphocytes, progenitors, and stem作者: 里程碑 時間: 2025-3-25 02:57
Bayreuth: Capital and Anti-capitalpidly evolving field of translational medicine. This approach has delivered exciting responses for some patients with lymphoid hematologic neoplasms, leading to recent US Food and Drug Administration approvals. Hematopoietic stem cellular gene therapy has also shown promising advances, with durable 作者: Root494 時間: 2025-3-25 03:35
Oppression and Resistance Timelinegen receptor T cells provide exciting potential for curative treatments to patients with cancers found intractable with current therapies. Toxicities are one of the main limiting factors for wide applicability of CAR-T-cell therapy. The major limiting adverse events include neurotoxicity and cytokin作者: Cpap155 時間: 2025-3-25 09:48 作者: Magisterial 時間: 2025-3-25 11:58 作者: 最高峰 時間: 2025-3-25 15:54
https://doi.org/10.1057/978-1-137-57664-4ll lymphocytic lymphoma (CLL/SLL) and B-cell acute lymphoblastic leukemia (B-ALL). However, targeting CD19 can result in prolonged B-cell aplasia. Given the clinical experience with the anti-CD20 monoclonal antibody rituximab with temporary B-cell aplasia, severe clinical consequence has not been ob作者: 適宜 時間: 2025-3-25 22:09
Organizational Identity and Firm Growthlogy and new developments in synthetic biology have led to an ability to engineer T cells to express antibody-like recognition molecules linked to T cell-activating domains (chimeric antigen receptors, CARs) and tumor-specific T cell receptors (TCRs) which redirect patient-derived T cells toward the作者: blithe 時間: 2025-3-26 03:12 作者: Leisureliness 時間: 2025-3-26 07:43 作者: Hypopnea 時間: 2025-3-26 10:19
Old Age in Nineteenth-Century Irelandof the potential of immunotherapy as a therapeutic strategy. In recent years, such skepticism has diminished significantly as clinical evidence increasingly demonstrates the effectiveness of manipulating the immune system to treat a variety of established tumors. Among components of the immune syste作者: 平庸的人或物 時間: 2025-3-26 16:00
https://doi.org/10.1057/978-1-137-58714-5re they continuously survey the local environment and inform cells of the immune system to modulate their responses. Under inflammatory conditions, DCs undergo terminal maturation and activation to become fully immunogenic. DC heterogeneity and differential activation states ultimately determine the作者: AFFIX 時間: 2025-3-26 18:39 作者: lobster 時間: 2025-3-26 23:28
Dave Cowan,Helen Carr,Alison Wallace the only therapy that has proven to be curative for hematological malignancies. The search for a more specific and, hopefully, less toxic therapeutic approach using immune system cells that are redirected toward the target of interest is needed and ongoing. This could be potentially accomplished by作者: 套索 時間: 2025-3-27 01:47 作者: 多嘴多舌 時間: 2025-3-27 05:33
Cell and Gene Therapies978-3-319-54368-0Series ISSN 2569-1376 Series E-ISSN 2569-135X 作者: 有其法作用 時間: 2025-3-27 12:24 作者: Irksome 時間: 2025-3-27 16:30
Most Recent Clinical Advances in CAR T Cell and Gene Therapy 2017/2018,ogenic disorders (Gardner et al., Blood 129:3322–3331, 2017) (refer to subsequent disease-specific chapters in the book). In this chapter, we will highlight the most recent and clinically relevant developments in the arena of gene-modified T-cell-based therapies and hematopoietic stem cellular gene 作者: Geyser 時間: 2025-3-27 18:50
Chimeric Antigen Receptor T Cells for Leukemias in Children: Methods, Data, and Challengesgation for treatment of relapsed ALL. Whole-genome sequencing has allowed characterization of the transcriptional profile of the leukemic cell, facilitating targeted therapy and leading us one step closer to precision medicine. In this rapidly evolving “race” for better and nontoxic treatments, we f作者: 賠償 時間: 2025-3-27 22:04 作者: 圓柱 時間: 2025-3-28 03:14
Cytotoxic T Cells for Infections: From Donor Specific to “Off the Shelf”the deficiencies in viral immunity post-transplant. In this review, we begin by detailing the advances made in producing single-virus-specific T cells, in particular for CMV and EBV, and then proceed to describe the progress in developing multi-virus-specific T cells and in broadening the repertoire作者: Ligneous 時間: 2025-3-28 09:48
Regulatory T Cells: Broadening Applicability even prevent this fatal complication in the clinical setting. Ultimately, researchers and clinicians want to find a way to establish long-lasting tolerance within the graft without diminishing the beneficial graft-versus-tumor/graft-versus-leukemia (GvT/GvL) effect..The chapter will give an overvie作者: Graduated 時間: 2025-3-28 11:38 作者: objection 時間: 2025-3-28 17:24 作者: 迅速飛過 時間: 2025-3-28 20:19
Mesenchymal Stem Cells: From Bench to Bedside and Backs the treatment of graft-versus-host disease (GvHD) and marrow failure. The initial studies confirmed the infusional safety of MSC given to HCT recipients and have paved the way for subsequent clinical research. Today, more than a decade later, the potential of MSC to improve outcomes after allogene作者: 思想流動 時間: 2025-3-29 00:37
Gene Therapy for Neoplastic Hematology in Transplant Settingcide gene therapies, gene suppression, or oncolytic viral and non-viral therapies. In this chapter, we will review the historical context of gene therapy and cellular engineering development for the treatment of hematological malignancies and, particularly, in the setting of hematopoietic cell trans作者: ticlopidine 時間: 2025-3-29 06:48
Gene Therapy for Nonmalignant Hematologyn of gene-editing platforms, including zinc-finger nuclease (ZFN), transcription activator-like effector nucleases (TALEN), and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9, offer exciting prospective strategies for further improving gene therapy by targeting the repair of作者: 半身雕像 時間: 2025-3-29 10:34
https://doi.org/10.1057/978-1-137-57085-7heless, the attractions of a component therapy approach to HCT are many including but not limited to (1) T-cell depletion by selection of CD34. cells, which can reduce GvHD, and (2) infused donor lymphocytes which can improve engraftment and treat leukemic relapse. Careful studies in the 1990s deter作者: induct 時間: 2025-3-29 12:20 作者: 擦試不掉 時間: 2025-3-29 17:56 作者: 發(fā)現(xiàn) 時間: 2025-3-29 20:28 作者: 牙齒 時間: 2025-3-30 01:43
,Conclusion: The Ombuds as “Third Way”,the deficiencies in viral immunity post-transplant. In this review, we begin by detailing the advances made in producing single-virus-specific T cells, in particular for CMV and EBV, and then proceed to describe the progress in developing multi-virus-specific T cells and in broadening the repertoire作者: 誘拐 時間: 2025-3-30 06:33 作者: 生命 時間: 2025-3-30 11:23
Old Age in Nineteenth-Century Irelandnormal and fully functional NK cells that are less inhibited by patient tumor. Despite these encouraging findings, NK cell therapy is limited by the lack of antigen specificity and by tumor escape likely resulting from the formation of a complex network of suppressive components in the tumor microen作者: left-ventricle 時間: 2025-3-30 13:20
https://doi.org/10.1057/978-1-137-58714-5n their own class I MHC molecules to autologous T cells regardless of the MHC alleles expressed by the antigen source. When compared with other APCs, like macrophages, DCs are much more efficient and can elicit responses from very low numbers of T cells. In this chapter we review such and other mech作者: IRK 時間: 2025-3-30 17:27 作者: STANT 時間: 2025-3-30 23:31 作者: Abrade 時間: 2025-3-31 03:08
